TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd (T:4502) reported on Monday a 55.1 percent jump in annual operating profit, buoyed by growing sales of bowel disease drug Entyvio and heartburn and ulcer drug Takecab.
Operating profit came in at 241.8 billion yen (1.6 billion pounds) for the year ended March, versus 155.9 billion yen a year ago. That was above an average estimate of 235.4 billion yen from 11 analysts polled by Thomson Reuters I/B/E/S.
For the current financial year, Takeda sees an operating profit of 201 billion yen.
The earnings come days after it agreed to acquire London-listed Shire (L:SHP) for $62 billion in a deal that will propel it into the top 10 rankings of global drugmakers.